Characterization of neutralizing monoclonal antibodies recognizing a 15-residues epitope on the spike protein HR2 region of severe acute respiratory syndrome coronavirus (SARS-CoV)

Journal of Biomedical Science

Volumn 12, Issue 5, 2005, Pages 711-727

  Lai, Szu Chia ^a   Chong, Pele Choi Sing ^b   Yeh, Chia Tsui ^a   Liu, Levent Shih Jen ^b   Jan, Jia Tsrong ^a   Chi, Hsiang Yun ^b   Liu, Hwan Wun ^a   Chen, Ann ^a   Wang, Yeau Ching ^a  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Heptad repeat region; Monoclonal antibodies; Neutralizing epitope; SARS CoV; Spike protein

Indexed keywords

ANTISERUM; EPITOPE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PEPTIDE; PEPTIDE CB119; RECOMBINANT PROTEIN; SPIKE PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL CELL; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; ESCHERICHIA COLI; IMMUNIZATION; IMMUNOFLUORESCENCE TEST; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; RAT; SARS CORONAVIRUS; VERO CELL; WESTERN BLOTTING;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; BASE SEQUENCE; BLOTTING, WESTERN; DNA PRIMERS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; SARS VIRUS; VIRAL ENVELOPE PROTEINS;

ANIMALIA; CORONAVIRUS; ESCHERICHIA COLI; SARS CORONAVIRUS; SARS COV;

EID: 27744539479     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1007/s11373-005-9004-3     Document Type: Article

References (34)

1. Drosten C., Gunther S., Preiser W., van der Werf S., Brodt H.R., Becker S., Rabenau H., Panning M., Kolesnikova L., Fouchier R.A., Berger A., Burguiere A.M., Cinatl J., Eickmann M., Escriou N., Grywna K., Kramme S., Manuguerra J.C., Muller S., Rickerts V., Sturmer M., Vieth S., Klenk H.D., Osterhaus A.D., Schmitz H. and Doerr H.W., Identification of a novel coronavirus in patients with severe acute respiratory syndrome. New Engl. J. Med. 348: 1967-1976, 2003.
2. Ksiazek T.G., Erdman D., Goldsmith C.S., Zaki S.R., Peret T., Emery S., Tong S., Urbani C., Comer J.A., Lim W., Rollin P.E., Dowell S.F., Ling A.E., Humphrey C.D., Shieh W.J., Guarner J., Paddock C.D., Rota P., Fields B., DeRisi J., Yang J.Y., Cox N., Hughes J.M., LeDuc J.W., Bellini W.J. and Anderson L.J., A novel coronavirus associated with severe acute respiratory syndrome. New Engl. J. Med. 348: 1953-1966, 2003.
3. Peiris J.S., Lai ST., Poon L.L., Guan Y., Yam L.Y., Lim W., Nicholls J., Yee W.K., Yan W.W., Cheung M.T., Cheng V.C., Chan K.H., Tsang D.N., Yung R.W., Ng T.K. and Yuen K.Y., Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361: 1319-1325, 2003.
4. Lai, M.M.C., Holmes K.V., et al. In: Knipe D.M. and Howley P.M. (Eds), Coronaviridae: The Viruses and their Replication. Lippincott Williams and Wilkins, London, 2001, 1163-1185.
5. Fazakerley J.K., Parker S.E., Bloom F. and Buchmeier M.J., The V5A13.1 envelope glycoprotein deletion mutant of mouse hepatitis virus type-4 is neuroattenuated by its reduced rate of spread in the central nervous system. Virology 187: 178-188, 1992.
6. Laude H., Van Reeth K. and Pensaert M., Porcine respiratory coronavirus: molecular features and virus-host interactions. Vet. Res. 24: 125-150, 1993.
7. Banner L.R., Keck J.G. and Lai M.M., A clustering of RNA recombination sites adjacent to a hypervariable region of the peplomer gene of murine coronavirus. Virology 175: 548-555, 1990.
8. Cavanagh D., Davis P.J. and Mockett A.P., Amino acids within hypervariable region 1 of avian coronavirus IBV (Massachusetts serotype) spike glycoprotein are associated with neutralization epitopes. Virus Res. 11: 141-150, 1988.
9. Daniel C., Anderson R., Buchmeier M.J., Fleming J.O., Spaan W.J., Wege H. and Talbot P.J., Identification of an immunodominant linear neutralization domain on the S2 portion of the murine coronavirus spike glycoprotein and evidence that it forms part of complex tridimensional structure. J. Virol. 67: 1185-1194, 1993.
10. Gallagher T.M., Parker S.E. and Buchmeier M.J., Neutralization-resistant variants of a neurotropic coronavirus are generated by deletions within the amino-terminal half of the spike glycoprotein. J. Virol. 64: 731-741, 1990.
11. LaBarre D.D. and Lowy R.J., Improvements in methods for calculating virus titer estimates from TCID50 and plaque assays. J. Virol. Methods 96: 107-126, 2001.
12. Wang Y.C., Jian T.Y., Tarn L.J., Hung Y.W., Chao H.Y., Ji D.D. and Liu H.W., Development of a recombinant protein-based enzyme-linked immunosorbent assay and its applications in field surveillance of rodent mice for presence of immunoglobulin G against Orientia tsutsugamushi. Clin. Diagn. Lab. Immun. 10: 451-458, 2003.
13. Kohler G. and Milstein C., Continuous cultures of fused cells secreting antibody of predefined specificity. 1975. Biotechnology 24: 524-526, 1992.
14. Kim M.K. and Kang J.S., Orientia tsutsugamushi suppresses the production of inflammatory cytokines induced by its own heat-stable component in murine macrophages. Microb. Pathog. 31: 145-150, 2001.
15. Sui J., Li W., Murakami A., Tamin A., Matthews L.J., Wong S.K., Moore M.J., Tallarico A.S., Olurinde M., Choe H., Anderson L.J., Bellini W.J., Farzan M. and Marasco W.A., Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc. Natl. Acad. Sci. USA 101: 2536-2541, 2004.
16. Ausubel F.M., Brent R., Kingston R.E., Moore D.D., Seidman J.G., Smith J.A. and Struhl K., Short Protocols in Molecular Biology 2. Greene Publishing Associates and John Wiley & Sons, New York, 1992, pp. 1-25.
17. Bewley C.A., Louis J.M., Ghirlando R. and Clore G.M., Design of a novel peptide inhibitor of HIV fusion that disrupts the internal trimeric coiled-coil of gp41. J. Biol. Chem. 277: 14238-14245, 2002.
18. Bosch B.J., van der Zee R., de Haan C.A. and Rottier P.J., The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J. Virol. 77: 8801-8811, 2003.
19. Ghosh J.K., Peisajovich S.G., Ovadia M. and Shai Y., Structure-function study of a heptad repeat positioned near the transmembrane domain of Sendai virus fusion protein which blocks virus-cell fusion. J. Biol. Chem. 273: 27182-27190, 1998.
20. Medinas R.J., Lambert D.M. and Tompkins W.A., C-Terminal gp40 peptide analogs inhibit feline immunodeficiency virus: cell fusion and virus spread. J. Virol. 76: 9079-9086, 2002.
21. Pinon J.D., Kelly S.M., Price N.C., Flanagan J.U. and Brighty D.W., An antiviral peptide targets a coiled-coil domain of the human T-cell leukemia virus envelope glycoprotein. J. Virol. 77: 3281-3290, 2003.
22. Pritsker M., Jones P., Blumenthal R. and Shai Y., A synthetic all D-amino acid peptide corresponding to the N-terminal sequence of HIV-1 gp41 recognizes the wild-type fusion peptide in the membrane and inhibits HIV-1 envelope glycoprotein-mediated cell fusion. Proc. Natl. Acad. Sci. USA 95: 7287-7292, 1998.
23. Rapaport D., Ovadia M. and Shai Y., A synthetic peptide corresponding to a conserved heptad repeat domain is a potent inhibitor of Sendai virus-cell fusion: an emerging similarity with functional domains of other viruses. Embo J. 14: 5524-5531, 1995.
24. Tomasi M., Pasti C., Manfrinato C., Dallocchio F. and Bellini T., Peptides derived from the heptad repeat region near the C-terminal of Sendai virus F protein bind the hemagglutinin-neuraminidase ectodomain. FEBS Lett. 536: 56-60, 2003.
25. Yang C. and Compans R.W., Analysis of the murine leukemia virus R peptide: delineation of the molecular determinants which are important for its fusion inhibition activity. J. Virol. 71: 8490-8496, 1997.
26. Young J.K., Hicks R.P., Wright G.E. and Morrison T.G., Analysis of a peptide inhibitor of paramyxovirus (NDV) fusion using biological assays NMR, and molecular modeling. Virology 238: 291-304, 1997.
27. Zhao X., Singh M., Malashkevich V.N. and Kim P.S., Structural characterization of the human respiratory syncytial virus fusion protein core. Proc. Natl. Acad. Sci. USA 97: 14172-14177, 2000.
28. Yuan K., Yi L., Chen J., Qu X., Qing T., Rao X., Jiang P., Hu J., Xiong Z., Nie Y., Shi X., Wang W., Ling C., Yin X., Fan K., Lai L., Ding M. and Deng H., Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein. Biochem. Biophys. Res. Commun. 319: 746-752, 2004.
29. Liu S., Xiao G., Chen Y., He Y., Niu J., Escalante C.R., Xiong H., Farmar J., Debnath A.K., Tien P. and Jiang S., Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet 363: 938-947, 2004.
30. Tripet B., Howard M.W., Jobling M., Holmes R.K., Holmes K.V. and Hodges R.S., Structural Characterization of the SARS-Coronavirus Spike S Fusion Protein Core. J. Biol. Chem. 279: 20836-20849, 2004.
31. Xu Y., Zhu J., Liu Y., Lou Z., Yuan F., Liu Y., Cole D.K., Ni L., Su N., Qin L., Li X., Bai Z., Bell J.I., Pang H., Tien P., Gao G.F. and Rao Z., Characterization of the heptad repeat regions HR1 and HR2, and design of a fusion core structure model of the spike protein from severe acute respiratory syndrome (SARS) coronavirus. Biochemistry 43: 14064-14071, 2004.
32. Bosch B.J., Martina B.E., Van Der Zee R., Lepault J., Haijema B.J., Versluis C., Heck A.J., De Groot R., Osterhaus A.D. and Rottier P.J., Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. Proc. Natl. Acad. Sci. USA 101: 8455-8460, 2004.
33. Zhu J., Xiao G., Xu Y., Yuan F., Zheng C., Liu Y., Yan H., Cole D.K., Bell J.I., Rao Z., Tien P. and Gao G.F., Following the rule: formation of the 6-helix bundle of the fusion core from severe acute respiratory syndrome coronavirus spike protein and identification of potent peptide inhibitors. Biochem. Biophys. Res. Commun. 319: 283-288, 2004.
34. Li W., Moore M.J., Vasilieva N., Sui J., Wong S.K., Berne M.A., Somasundaran M., Sullivan J.L., Luzuriaga K., Greenough T.C., Choe H. and Farzan M., Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426: 450-454, 2003.